TRLV Trulieve Cannabis Corp.
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 1754195 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.1%
TTM net income YoY-218.5%
TTM EPS YoY-245.5%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—
Margins
Gross margin60.6%
Operating margin-25.6%
Net margin-41.3%
FCF margin16.2%
EBITDA margin-16.1%
Returns
ROE-45.2%
ROA-17.7%
ROIC (approx.)-24.8%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets63.6%
Debt / equity0.25x
Current ratio5.52x
Interest coverage-5.25x
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-27.2%
Payout ratio—
Capex / revenue6.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $230.22M | $270.95M | $286.75M | $293.15M | $288.19M | $302.09M | $297.76M | $301.14M |
| Cost of revenue | $82.19M | $108.66M | $116.67M | $117.98M | $118.33M | $119.16M | $114.54M | $114.13M |
| Gross profit | $148.02M | $162.29M | $170.08M | $175.16M | $169.86M | $182.93M | $183.22M | $187.02M |
| SG&A expense | $87.84M | $101.77M | $104.89M | $126.31M | $99.02M | $101.12M | $118.77M | $157.94M |
| Operating income | $42.49M | -$370.52M | $35.73M | $15.30M | $42.24M | $52.63M | $33.33M | $1.31M |
| Interest expense | $11.97M | $12.76M | $13.32M | $14.68M | $16.09M | $16.39M | $16.30M | $14.62M |
| Pretax income | $27.02M | -$383.40M | $25.22M | $2.94M | $29.30M | $38.90M | $20.33M | -$12.90M |
| Income tax | $26.25M | $21.97M | $21.86M | $47.89M | $53.04M | $54.72M | $52.46M | $47.57M |
| Net income | $774,000 | -$406.06M | $2.28M | -$43.59M | -$28.78M | -$16.11M | -$33.76M | -$61.56M |
| EBITDA | $60.19M | -$344.80M | $65.47M | $44.72M | $71.69M | $82.06M | $62.65M | $29.95M |
| EPS (basic) | 0.00 | — | — | — | -0.14 | — | -0.16 | — |
| EPS (diluted) | 0.00 | — | — | — | -0.14 | — | -0.16 | — |
| Weighted avg. shares (diluted) | 200.61M | 192.71M | 197.76M | — | 191.28M | 191.20M | 191.13M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $326.69M | $325.42M | $352.88M | $255.53M | $449.20M | $392.58M | $328.45M | $238.80M |
| Short-term investments | — | — | — | $0 | $0 | $0 | $0 | $60.39M |
| Receivables | $3.75M | $3.94M | $14.05M | $10.50M | $10.49M | $10.76M | $10.26M | $8.29M |
| Inventory | $190.83M | $186.87M | $242.32M | $242.30M | $243.29M | $241.46M | $239.28M | $231.37M |
| Current assets | $562.78M | $564.83M | $652.96M | $562.72M | $756.45M | $711.38M | $649.38M | $604.56M |
| PP&E, net | $592.93M | $583.99M | $676.94M | $670.44M | $693.98M | $699.04M | $710.15M | $716.05M |
| Goodwill | $325.62M | $325.62M | $483.90M | $483.90M | $483.90M | $483.90M | $483.90M | $483.90M |
| Intangibles | $335.04M | $300.44M | $780.75M | $798.37M | $815.31M | $832.38M | $848.80M | $859.48M |
| Total assets | $2.12B | $2.08B | $2.78B | $2.70B | $2.94B | $2.92B | $2.89B | $2.87B |
| Current liabilities | $101.97M | $95.06M | $124.16M | $126.94M | $124.13M | $123.84M | $136.67M | $138.49M |
| Long-term debt | $196.01M | $195.82M | $195.64M | $136.74M | $366.12M | $365.68M | $365.25M | $364.84M |
| Total debt | $196.01M | $195.82M | $195.64M | $136.74M | $366.12M | $365.68M | $365.25M | $364.84M |
| Total liabilities | $1.35B | $1.31B | $1.63B | $1.55B | $1.76B | $1.71B | $1.67B | $1.62B |
| Shareholders' equity | $773.19M | $767.46M | $1.17B | $1.16B | $1.20B | $1.23B | $1.23B | $1.26B |
| Net debt | -$130.68M | -$129.60M | -$157.24M | -$118.79M | -$83.08M | -$26.90M | $36.80M | $126.03M |
| Shares outstanding | 170.60M | 192.38M | 192.31M | 192.31M | 191.14M | 191.10M | 191.08M | 191.01M |
| Cash flow statement | ||||||||
| Operating cash flow | $74.42M | $53.14M | $55.71M | $59.22M | $76.77M | $86.09M | $51.13M | $30.68M |
| Capital expenditure | $29.02M | $21.01M | $13.48M | $3.41M | $16.60M | $16.01M | $20.80M | $42.70M |
| Free cash flow | $45.40M | $32.13M | $42.22M | $55.80M | $60.17M | $70.08M | $30.33M | -$12.02M |
| Investing cash flow | -$68.74M | -$74.86M | -$13.19M | -$5.89M | -$15.38M | -$8.63M | $43.02M | -$23.18M |
| Financing cash flow | -$4.42M | -$5.74M | $54.83M | -$255.39M | -$4.77M | -$5.83M | -$4.50M | -$6.36M |
| Depreciation & amortization | $17.71M | $25.72M | $29.74M | $29.42M | $29.46M | $29.43M | $29.33M | $28.64M |
| Stock-based compensation | $5.90M | $6.91M | $4.14M | $3.98M | $5.79M | $6.76M | $3.94M | $4.62M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.